Image

Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

The study aim to investigate the relationship between cutaneous adverse events and quality of life in patients taking immune check point inhibitor or cyclin-dependent kinase (CDK) 4 and 6 inhibitors by two steps. In the first one, it will be investigated the relationship between the skin toxicity related to the use selected therapies and the quality of life of patients already receiving these therapies for treatment of their cancer. In the second one, it will be evaluated the relationship between skin toxicity and quality of life over three months of treatment in patients initially naïve for selected therapies. Cancer included in the analysis are NSCLC, renal cancer, gastric cancer, breast cancer, bladder cancer, melanoma, squamous cell carcinoma of the head and neck.

Eligibility

Inclusion Criteria:

(for all Groups)

  1. Age ≥ 18 years.
  2. Histological diagnosis of solid tumor.
  3. Patient able to complete the questionnaires submitted during the study.
  4. Signed written informed consent. (for Group I) Patients already under treatment for at least three months with anti-PD1/PDL1/ CTLA4 or cyclin-dependent kinase (CDK) inhibitors for any type of cancer. Treatment considered for each cancer are only those approved by AIFA for each tumor.
        (for Group II) Patients eligible for treatment with anti-PD1/PDL1/ CTLA4 or
        cyclin-dependent kinase (CDK) inhibitors for any type of cancer. Treatment considered for
        each cancer are only those approved by AIFA for each tumor.
        Exclusion Criteria (for all Groups):
          1. Age < 18 y.o.
          2. Skin diseases or alterations present before the beginning of anti-PD1/PDL1 or
             cyclin-dependent kinase (CDK) inhibitors.
          3. Chronic use of steroids.
          4. Previous psychiatric disorders or patients taking antidepressant.
          5. Refusal to sign written informed consent.

Study details

Lung Cancer, Breast Cancer, Kidney Cancer, Bladder Cancer, Gastric Cancer

NCT05878964

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

19 March 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.